HK Stock Market Move | INNOVENT BIO (01801) rises over 3%; IBI3003 clinical data validate leading position in MM TCE; Phase III registrational study has been advanced in China.

INNOVENT BIO (01801) rose over 3%, up 2.97% as of press time at HK$90, with turnover of HK$362 million. On the news front, CMBI issued a research report stating that INNOVENT BIO presented Phase I clinical data for IBI3003 in 102 patients with R/R MM at IMS 2026. The report noted that IBI3003, as a BCMAGPRC5DCD3 trispecific TCE, demonstrated positive early clinical results in relapsed/refractory multiple myeloma, supporting its position among the leading assets in this field. The bank believes that China's MM TCE market remains in its early stages, with approved overseas products not yet included in medical insurance, and high prices limiting penetration; domestic substitution is expected to broaden market space. IBI3003 has advanced a Phase III registrational study in China, and the company is also conducting Phase I/II studies in the US, positioning it as one of the key drivers of globalization. Near-term catalysts include data for IBI363, IBI343, and IBI3001, which are expected to be disclosed at ESMO in October.